JAN 28, 2017 5:35 PM PST

Gene Function now Revealed, Presents GI Cancer Drug Target

WRITTEN BY: Carmen Leitch

The entire genome of humans has been sequenced, but we still don’t know everything about every gene. Genes sometimes accumulate many names over years as they pass in and out of research labs and the exact characteristics and functions of various genes remains relatively unknown. New research is now shedding light on one such gene, known as Gpr182, and also known as G10D, HrhAMR, Gamrh, 7TMR, and ADMR. It is a receptor that is important in cellular signaling, a G-protein coupled receptor; one place it resides is the surface of special intestinal cells. This research, published in the Journal of Clinical Investigation, may also aid in the development of cancer therapeutics.

This is picture of a cross section of a mouse intestine. Each 'petal' on the fringe of the image is showing a villus -- a finger-like projection extending into the lumen of the small intestine. / Credit: Kathleen Caron Lab, UNC

"What makes this so exciting is that it's completely new," commented research leader Kathleen Caron, PhD, Professor and Chair of the Department of Cell Biology and Physiology at the UNC School of Medicine. "There was absolutely nothing known about this protein. I think these findings will be picked up on quickly, and I imagine it's going to fuel a lot of research on this receptor now."

Caron became interested in learning more about Gpr182 because it was thought to be a receptor for adrenomedullin, a hormone postulated to be involved in heart function, a focus of Caron’s research. It turns out that Gpr182 isn’t the receptor for that hormone. It took a transgenic mouse with a reporter tag to reveal more about its function.

"Of all the names it had over the years, the name that stuck was adrenomedullin receptor, or ADMR," said Caron, a member of the UNC Lineberger Comprehensive Cancer Center. "It sort of hung that way in the databases for a while, even as science moved forward and scientists found another receptor that is considered to be the real adrenomedullin receptor. A few labs looked at this protein and sort of scratched their heads, because it wasn't really doing what an adrenomedullin receptor should be doing. And then everyone sort of dropped it for a good dozen years."

The researchers were able to detect GPr182 on cells of the heart, lung and kidneys, and importantly, in cells of the undulating lining of the small intestine, the intestinal crypt. That is where the investigators put their focus. "In my undergraduate experience I had been in a gastrointestinal lab, and seeing that position within the intestinal crypt really sparked my interest," said Daniel Kechele, PhD, then a graduate student in Caron's lab, now a postdoctoral fellow at Cincinnati Children's Hospital. "My gastrointestinal background and the strong intestinal stem cell group at UNC made it possible to follow that lead and see where it would take us."

The cells of the crypt experience an incredible degree of turnover, producing 100 square feet of cells and fully replacing the intestinal lining every seven days or so. That high rate of proliferation, required to reduce the risk of infection, raises the chance of tumor growth. Kechle was intrigued by the role that Gpr182 might have in the balancing act played in intestinal proliferation.

Collaborators with expertise in studying the gene activity of intestinal stem cells came in to delve deeper. This tool opened up a whole new world," said Scott Magness, PhD of UNC. "All of a sudden we can use it to figure out how various genes of interest, like Gpr182, are expressed in both active and reserve stem cells, and how the gene might be functioning."

Their work showed that suppressing Gpr182 generally increased proliferation, and suggested that Gpr182 was acting as a brake on cell growth. "We don't necessarily think this gene is itself a driver of cancer, but it's possible that mutations in the gene could play a role in the severity of the cancer," explained Kechele.

When the scientists utilized a sort of chemotherapy model, ablating the active cells of a mouse intestine with radiation, reducing Gpr182 caused a huge increase in growth out of what was left of the stem cell population.

"That suggests this gene could be a target for therapy to speed up the regeneration of the gut lining after cancer treatment," said Magness. "By decreasing the expression of the Gpr182 protein, you might be able to induce the stem cells to respond more robustly in the regenerative phase, thus allowing doctors to use a higher or more effective therapeutic dosage without harming the normal functioning of the gut."

The green indicates the g protein-coupled receptor 182, which UNC researchers say could be vital in the fight against gastrointestinal cancers. / Credit: Kathleen Caron Lab, UNC

The researchers also looked at human patients; there was less Gpr182 in the colons of colorectal cancer patients compared to healthy colons. A similar decrease was confirmed in other types of cancer as well including breast and lung disease.

Gpr182 is being pursued as a drug target; the company Omeros claims to have a small molecule that is able to interact with Gpr182. The findings are certainly worth exploring as a new avenue for cancer therapeutics.

"I think it shows how passion and grit can really drive science in new and unexpected ways," said Caron. "It takes perseverance to keep asking questions and exploring things. If we had kept on assuming this was an adrenomedullin receptor, we would be missing the mark--and might have missed this exciting breakthrough."

You can see a talk from Dr. Caron in the video above, UNC - Chapel Hill presents "Genetic Research Tools for the Study of the Lymphatic Vascular System."


Sources: AAAS/Eurekalert! via UNC, Journal of Clinical Investigation

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
JAN 20, 2020
JAN 20, 2020
Ovarian Cancer Protein Accelerates Alzheimer's Neurodegeneration
Around 21,000 people in the US are diagnosed with ovarian cancer every year, while an estimated 5.8 million Americans have Alzheimer’s. Now, research...
JAN 11, 2020
JAN 11, 2020
Molecular Therapy to Self-Repair Nerve Cells
Neurodegenerative diseases such as Multiple Sclerosis (MS), Alzheimer's, and Huntington's Disease are predicated on damage to myelin on nerve cells...
MAR 01, 2020
MAR 01, 2020
Microbes Can Make Changes to Bile Acids That Alter Gene Expression
The microbes in our digestive tract can affect human health in many ways....
MAR 26, 2020
Cell & Molecular Biology
MAR 26, 2020
A Large Cavity is Discovered in a Tuberculosis Protein
Scientists have discovered something very unusual about a protein that is thought to be important to the development of tuberculosis....
APR 02, 2020
Chemistry & Physics
APR 02, 2020
How Particle Physicists can Lend a Hand to the Search for SARS-CoV-02 Cure, Explained
With vaccines at least one year away and no proven treatment for infection, the world has witnessed the loss of  20,000 lives due to the SARS-CoV-02 i...
APR 02, 2020
Cell & Molecular Biology
APR 02, 2020
Cooling Injured Brain Cells Can Aid Recovery
According to the CDC, in 2014 there were around 2.87 million incidences of TBI-related ER visits....
Loading Comments...